🇺🇸 Candida Antigen in United States

10 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 10

Most-reported reactions

1. Dermatitis Psoriasiform — 1 report (10%)
2. Drug Ineffective For Unapproved Indication — 1 report (10%)
3. Epidermodysplasia Verruciformis — 1 report (10%)
4. Guttate Psoriasis — 1 report (10%)
5. Haemorrhage — 1 report (10%)
6. Off Label Use — 1 report (10%)
7. Pain — 1 report (10%)
8. Papilloma Viral Infection — 1 report (10%)
9. Renal Impairment — 1 report (10%)
10. Therapy Non-Responder — 1 report (10%)

Source database →

Frequently asked questions

Is Candida Antigen approved in United States?

Candida Antigen does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Candida Antigen in United States?

University of Arkansas is the originator. The local marketing authorisation holder may differ — check the official source linked above.